Recently I published a list Was Jim Kramer right about these 11 stocks? In this article, we look at where Sarepta Therapeutics Inc. (NASDAQ: SRPT) represents against other stocks that Jim Kramer discusses.
The caller asked about Sarepta Therapeutics Inc. (NASDAQ: SRPT), a biotechnology company committed to RNA therapy. Kramer responded with cautionary optimism:
“What do you know, I haven’t seen it recently – what is it doing with RNA and some really severe illnesses? It’s about not making money, but getting out and making money. I’m not going to say no to it.”
Kramer missed this despite being cautiously positive as Salepta plunged 68.98%. Sarepta Therapeutics Inc. (NASDAQ: SRPT) focuses on precision genetic medicine, including RNA therapy for rare neuromuscular diseases such as Duchenne muscular dystrophy.
Laboratory technician wearing a white coat holding a microscope and examining a vial of biopharmaceuticals.
As of 2025, Cramer changed his opinion on stocks. This is what he said in 15th January when asked about it:
“You’re totally right. I don’t think RNA-based therapy companies are doing well. I wonder if this is something like an inverse halo effect for Moderna.
Overall, Srpt 2nd place On the list of stocks that Jim Kramer discusses. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold a greater commitment to providing higher returns and limited downside risk. If you’re looking for AI stocks that are more promising than SRPT and have a potential of 100 times upside, check out our report on this Cheapest AI stocks.
Read next: Best AI stocks to buy now and According to the billionaire, 30 best stocks to buy now.
Disclosure: None. This article was originally published Insider Monkey.
